Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arvinas, Inc. stock logo
ARVN
Arvinas
$7.89
-0.1%
$7.30
$5.90
$34.11
$580.28M2.171.47 million shs826,658 shs
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$2.90
+0.6%
$4.50
$2.19
$26.98
$309.68M0.672.22 million shs1.75 million shs
Xencor, Inc. stock logo
XNCR
Xencor
$8.41
+1.3%
$8.71
$7.16
$27.24
$599.26M0.85680,928 shs306,907 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arvinas, Inc. stock logo
ARVN
Arvinas
0.00%+4.66%+14.03%+20.29%-66.98%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
0.00%+14.47%+4.55%-43.44%-85.54%
Xencor, Inc. stock logo
XNCR
Xencor
0.00%+3.26%-7.84%-3.28%-54.84%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arvinas, Inc. stock logo
ARVN
Arvinas
3.0993 of 5 stars
4.32.00.00.00.02.51.3
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
4.8544 of 5 stars
4.22.00.04.71.75.01.3
Xencor, Inc. stock logo
XNCR
Xencor
4.0182 of 5 stars
3.42.00.03.92.00.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arvinas, Inc. stock logo
ARVN
Arvinas
2.55
Moderate Buy$20.29157.12% Upside
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
2.41
Hold$18.60542.27% Upside
Xencor, Inc. stock logo
XNCR
Xencor
2.75
Moderate Buy$28.00233.14% Upside

Current Analyst Ratings Breakdown

Latest ARVN, RCKT, and XNCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $5.00
6/3/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$34.00 ➝ $11.00
6/2/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$24.00
6/2/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.00
6/1/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/30/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ In-Line$5.00
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$32.00 ➝ $9.00
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $8.00
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$51.00 ➝ $19.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arvinas, Inc. stock logo
ARVN
Arvinas
$263.40M2.19N/AN/A$8.17 per share0.97
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
N/AN/AN/AN/A$5.08 per shareN/A
Xencor, Inc. stock logo
XNCR
Xencor
$127.23M4.70N/AN/A$9.63 per share0.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arvinas, Inc. stock logo
ARVN
Arvinas
-$198.90M-$0.66N/AN/AN/A-10.92%-7.74%-4.11%7/29/2025 (Estimated)
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$258.75M-$2.63N/AN/AN/AN/A-64.92%-56.13%8/4/2025 (Estimated)
Xencor, Inc. stock logo
XNCR
Xencor
-$232.62M-$3.06N/AN/AN/A-181.17%-31.94%-22.19%8/4/2025 (Estimated)

Latest ARVN, RCKT, and XNCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q2 2025
Arvinas, Inc. stock logo
ARVN
Arvinas
-$0.87N/AN/AN/A$34.42 millionN/A
5/13/2025Q1 2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$0.58-$0.56+$0.02N/AN/AN/A
5/8/2025Q1 2025
Xencor, Inc. stock logo
XNCR
Xencor
-$0.60-$0.66-$0.06-$0.66$23.44 million$32.73 million
5/5/2025Q1 2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$0.59-$0.56+$0.03-$0.56$0.80 millionN/A
5/1/2025Q1 2025
Arvinas, Inc. stock logo
ARVN
Arvinas
-$0.93$1.14+$2.07$1.14$41.87 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arvinas, Inc. stock logo
ARVN
Arvinas
N/AN/AN/AN/AN/A
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
N/AN/AN/AN/AN/A
Xencor, Inc. stock logo
XNCR
Xencor
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arvinas, Inc. stock logo
ARVN
Arvinas
N/A
4.58
4.58
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
0.05
9.19
9.19
Xencor, Inc. stock logo
XNCR
Xencor
0.16
5.89
5.89

Institutional Ownership

CompanyInstitutional Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
95.19%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
98.39%
Xencor, Inc. stock logo
XNCR
Xencor
N/A

Insider Ownership

CompanyInsider Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
4.73%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
24.76%
Xencor, Inc. stock logo
XNCR
Xencor
4.76%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arvinas, Inc. stock logo
ARVN
Arvinas
42072.99 million69.54 millionOptionable
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
240106.79 million80.35 millionOptionable
Xencor, Inc. stock logo
XNCR
Xencor
28071.17 million67.78 millionOptionable

Recent News About These Companies

Xencor Reports First Quarter 2025 Financial Results
Xencor initiated with an Outperform at William Blair

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arvinas stock logo

Arvinas NASDAQ:ARVN

$7.89 -0.01 (-0.11%)
Closing price 07/3/2025 02:37 PM Eastern
Extended Trading
$7.96 +0.07 (+0.87%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Rocket Pharmaceuticals stock logo

Rocket Pharmaceuticals NASDAQ:RCKT

$2.90 +0.02 (+0.56%)
Closing price 07/3/2025 03:49 PM Eastern
Extended Trading
$2.89 -0.01 (-0.21%)
As of 07/3/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Xencor stock logo

Xencor NASDAQ:XNCR

$8.40 +0.11 (+1.27%)
Closing price 07/3/2025 01:23 PM Eastern
Extended Trading
$8.40 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.